Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone
Objectives: Both Zoledronic acid and denosumab have been utilized in neo-adjuvant setting for facilitating surgery and downsizing the lesion in Giant cell tumor (GCT). This study is aimed at comparing Zoledronic acid and Denosumab, when used in neo-adjuvant setting, in terms of radiological and clin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-07-01
|
| Series: | Journal of Orthopaedic Surgery |
| Online Access: | https://doi.org/10.1177/23094990211007565 |
| _version_ | 1818671646216552448 |
|---|---|
| author | Himanshu Kanwat Roshan Banjara Venkatesan Sampath Kumar Abdul Majeed Shivanand Gamnagatti Shah Alam Khan |
| author_facet | Himanshu Kanwat Roshan Banjara Venkatesan Sampath Kumar Abdul Majeed Shivanand Gamnagatti Shah Alam Khan |
| author_sort | Himanshu Kanwat |
| collection | DOAJ |
| description | Objectives: Both Zoledronic acid and denosumab have been utilized in neo-adjuvant setting for facilitating surgery and downsizing the lesion in Giant cell tumor (GCT). This study is aimed at comparing Zoledronic acid and Denosumab, when used in neo-adjuvant setting, in terms of radiological and clinical outcomes in GCT undergoing surgical intervention. Patients and Methods: Patients undergoing surgical intervention for GCT who received either denosumab or Zoledronic acid as neoadjuvant agents were retrospectively analyzed for reduction in tumor load radiologically, change in surgical plan after therapy, facilitation of surgery, therapy related complications, cost of treatment, rate of local recurrence and clinical outcomes. Results: Twenty patients received denosumab and 19 patients received Zoledronic acid as neoadjuvant agent. There was no significant difference in radiological outcomes, facilitation of surgery and clinical outcomes at end of follow-up. Zoledronic acid group had lower number of recurrences, however, not statistically significant. Therapy with Zoledronic acid was significantly cheaper (p = 0.001). Conclusion: Zoledronic acid is a cheaper alternative to denosumab in terms of solidification of lesion, reducing recurrence rates and improving clinical outcomes. Larger prospective studies required to further delineate this outcome with Zoledronic acid. |
| first_indexed | 2024-12-17T07:27:18Z |
| format | Article |
| id | doaj.art-1e385eb953614d298f95b85dcff0447b |
| institution | Directory Open Access Journal |
| issn | 2309-4990 |
| language | English |
| last_indexed | 2024-12-17T07:27:18Z |
| publishDate | 2021-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Orthopaedic Surgery |
| spelling | doaj.art-1e385eb953614d298f95b85dcff0447b2022-12-21T21:58:35ZengSAGE PublishingJournal of Orthopaedic Surgery2309-49902021-07-012910.1177/23094990211007565Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of boneHimanshu Kanwat0Roshan Banjara1Venkatesan Sampath Kumar2Abdul Majeed3Shivanand Gamnagatti4Shah Alam Khan5 Department of Orthopaedics, All India Institute of medical sciences, New Delhi, India Department of Orthopaedics, All India Institute of medical sciences, New Delhi, India Department of Orthopaedics, All India Institute of medical sciences, New Delhi, India Department of Orthopaedics, All India Institute of medical sciences, New Delhi, India Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India Department of Orthopaedics, All India Institute of medical sciences, New Delhi, IndiaObjectives: Both Zoledronic acid and denosumab have been utilized in neo-adjuvant setting for facilitating surgery and downsizing the lesion in Giant cell tumor (GCT). This study is aimed at comparing Zoledronic acid and Denosumab, when used in neo-adjuvant setting, in terms of radiological and clinical outcomes in GCT undergoing surgical intervention. Patients and Methods: Patients undergoing surgical intervention for GCT who received either denosumab or Zoledronic acid as neoadjuvant agents were retrospectively analyzed for reduction in tumor load radiologically, change in surgical plan after therapy, facilitation of surgery, therapy related complications, cost of treatment, rate of local recurrence and clinical outcomes. Results: Twenty patients received denosumab and 19 patients received Zoledronic acid as neoadjuvant agent. There was no significant difference in radiological outcomes, facilitation of surgery and clinical outcomes at end of follow-up. Zoledronic acid group had lower number of recurrences, however, not statistically significant. Therapy with Zoledronic acid was significantly cheaper (p = 0.001). Conclusion: Zoledronic acid is a cheaper alternative to denosumab in terms of solidification of lesion, reducing recurrence rates and improving clinical outcomes. Larger prospective studies required to further delineate this outcome with Zoledronic acid.https://doi.org/10.1177/23094990211007565 |
| spellingShingle | Himanshu Kanwat Roshan Banjara Venkatesan Sampath Kumar Abdul Majeed Shivanand Gamnagatti Shah Alam Khan Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone Journal of Orthopaedic Surgery |
| title | Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone |
| title_full | Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone |
| title_fullStr | Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone |
| title_full_unstemmed | Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone |
| title_short | Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone |
| title_sort | comparison of denosumab and zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone |
| url | https://doi.org/10.1177/23094990211007565 |
| work_keys_str_mv | AT himanshukanwat comparisonofdenosumabandzoledronicacidasneoadjuvanttherapyinpatientswithgiantcelltumorofbone AT roshanbanjara comparisonofdenosumabandzoledronicacidasneoadjuvanttherapyinpatientswithgiantcelltumorofbone AT venkatesansampathkumar comparisonofdenosumabandzoledronicacidasneoadjuvanttherapyinpatientswithgiantcelltumorofbone AT abdulmajeed comparisonofdenosumabandzoledronicacidasneoadjuvanttherapyinpatientswithgiantcelltumorofbone AT shivanandgamnagatti comparisonofdenosumabandzoledronicacidasneoadjuvanttherapyinpatientswithgiantcelltumorofbone AT shahalamkhan comparisonofdenosumabandzoledronicacidasneoadjuvanttherapyinpatientswithgiantcelltumorofbone |